CHICAGO, Aug 14: GlaxoSmithKline and Shionogi Co. Ltd. today said they have completed the initial clinical study for an experimental HIV/AIDS drug that blocks viral replication by preventing its integration into the genetic material of human immune cells.
The drug, called 364735, belongs to a new class of anti-HIV drugs called integrase inhibitors and is being developed by a joint venture between Glaxo and Shionogi.
Results from the Phase I study of 364735, conducted in the United States to assess the drug's safety, are being submitted for presentation at a medical conference in 2007. A Phase II study is planned to start in late 2006 in HIV-infected adults.
REUTERS
The drug, called 364735, belongs to a new class of anti-HIV drugs called integrase inhibitors and is being developed by a joint venture between Glaxo and Shionogi.
Results from the Phase I study of 364735, conducted in the United States to assess the drug's safety, are being submitted for presentation at a medical conference in 2007. A Phase II study is planned to start in late 2006 in HIV-infected adults.
REUTERS
Oneindia Login